

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10618088
	Filing Date		2003-07-14
	First Named Inventor	Elizabeth JAFFE	
	Art Unit	1643	
	Examiner Name	Gussow, Anne	
	Attorney Docket Number	001107.00363	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.		T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10618088
Filing Date	2003-07-14
First Named Inventor	Elizabeth JAFFE
Art Unit	1643
Examiner Name	Gussow, Anne
Attorney Docket Number	001107.00363

/AMG/	1	BODEY, BODEY, SIEGEL, and KAISER. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Research, 2000. Vol. 20, pages 2665-2676.	<input type="checkbox"/>
/AMG/	2	LEE, WANG, NIELSEN, WUNDERLICH, MIGUELES, CONNORS, STEINBERG, ROSENBERG, and MARINCOLA. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. Journal of Immunology, 1999. Vol. 163, pages 6292-6300.	<input type="checkbox"/>
/AMG/	3	FORNI, LOLLINI, MUSIANI, and COLOMBO. Immunoprevention of cancer: is the time ripe? Cancer Research, 2000. Vol. 60, pages 2571-2575.	<input type="checkbox"/>
/AMG/	4	GURA. Systems for identifying new drugs are often faulty. Science, 1997. Vol. 278, pages 1041-1042.	<input type="checkbox"/>
/AMG/	5	DE GRUIJL and CUIEL. Cancer vaccine strategies get bigger and better. Nature Medicine, 1999. Vol. 5, pages 1124-1125.	<input type="checkbox"/>
/AMG/	6	CHATTERJEE, FOON, and KOHLER. Idiotype antibody immunotherapy of cancer. Cancer Immunology Immunotherapy, 1994. Vol. 38, pages 75-82.	<input type="checkbox"/>
/AMG/	7	Non-Final Office Action dated March 10, 2010 in co-pending U.S. Patent Application No. 12/210,604.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Anne M. Gussow/	Date Considered	05/25/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.